Pharmacy Articles

Pharmacy

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

The U.S. Food and Drug Administration approved INVEGA SUSTENNA extended–release injectable suspension for the acute and maintenance treatment of schizophrenia in adults. It is the first once–monthly, long–acting, injectable atypical antipsychotic approved in the U.S. for this use. Janssen, Division of Ortho–McNeil–Janssen Pharmaceuticals, Inc, will market INVEGA SUSTENNA in the U.S.

Today in Drug Approvals...keeping you current

Boston Scientific Announces FDA Clearance and CE Mark for WallFlex Fully Covered Esophageal Stent
Boston Scientific, 11/24/09

Dendreon Receives FDA Acknowledgement of Complete Response
Dendreon Coproration, 11/23/09

ImmunoGen, Inc. Announces Second License Taken by Amgen for Right to Use the Companys TAP Technology
ImmunoGen, Inc., 11/20/09


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Send this Summary to a Colleague

Enter email address